Get the Stockscreener App
6.42
2.72%
0.17
Shattuck Labs Inc stock is traded at $6.42, with a volume of 442.62K.
It is up +2.72% in the last 24 hours and up +60.50% over the past month.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
See More
Previous Close:
$6.25
Open:
$6.07
24h Volume:
442.62K
Relative Volume:
0.67
Market Cap:
$459.44M
Revenue:
$1,000.00K
Net Income/Loss:
$-48.81M
P/E Ratio:
-8.2978
EPS:
-0.7737
Net Cash Flow:
$-39.95M
1W Performance:
+1.74%
1M Performance:
+60.50%
6M Performance:
+170.89%
1Y Performance:
+552.70%
1-Day Range:
$6.06
$6.50
1-Week Range:
$5.93
$6.64
52-Week Range:
$0.6922
$6.8095
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
6.42 | 459.44M | 1,000.00K | -48.81M | -39.95M | -0.7737 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Resumed | Needham | Buy |
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Dec-01-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-08-25 | Initiated | Wedbush | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aug Catalysts: Is Shattuck Labs Inc a top pick in the sectorLong Setup & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Breakouts Watch: Is Shattuck Labs Inc stock a value trap2026 Retail & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
STTK PE Ratio & Valuation, Is STTK Overvalued - Intellectia AI
Shattuck Labs (STTK) price target increased by 37.93% to 10.20 - MSN
Shattuck Labs (NASDAQ:STTK) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Shattuck Labs: Surviving In An AI World Is Going To Be Tough (NASDAQ:STTK) - Seeking Alpha
Gap Down: Will Shattuck Labs Inc stock benefit from M AEarnings Growth Report & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Aug Wrap: Can Shattuck Labs Inc navigate macro headwinds2026 Trade Ideas & High Accuracy Swing Entry Alerts - baoquankhu1.vn
STTK Stock Price, Quote & Chart | SHATTUCK LABS INC (NASDAQ:STTK) - ChartMill
Institution Moves: Is Shattuck Labs Inc a turnaround story2026 Bull vs Bear & Accurate Intraday Trading Signals - baoquankhu1.vn
MACD Signal: Will Shattuck Labs Inc benefit from green energy policies2026 Fundamental Recap & Target Return Focused Picks - baoquankhu1.vn
FOMO Trade: Is Shattuck Labs Inc stock a value trap2026 Levels & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aug PostEarnings: What are the risks of holding Shattuck Labs Inc2026 Trading Recap & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Shattuck Labs (STTK) to Release Earnings on Thursday - MarketBeat
Profit Recap: What is the target price for Stardust Power Inc stockEarnings Summary Report & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Value Recap: Is The Hershey Company stock heavily shorted2026 PostEarnings & Weekly Breakout Watchlists - baoquankhu1.vn
STTK Technical Analysis & ETF Price Forecast - Intellectia AI
Short Interest in Shattuck Labs, Inc. (NASDAQ:STTK) Drops By 16.5% - MarketBeat
Shattuck Labs Receives $10 Price Target from Analysts - National Today
Prosight Management Trims Stake in Shattuck Labs - National Today
Analysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Oruka Therapeutics (ORKA) and Option Care Health (OPCH) - The Globe and Mail
Prosight Management LP Sells 1,187,740 Shares of Shattuck Labs, Inc. $STTK - MarketBeat
Shattuck Labs (STTK): Citigroup Raises Price Target to $7, Maint - GuruFocus
Citigroup Boosts Shattuck Labs (NASDAQ:STTK) Price Target to $7.00 - MarketBeat
Citi Increases Price Target for Shattuck Labs (STTK) with Potent - GuruFocus
Will Shattuck Labs Inc benefit from green energy policies2026 PreEarnings & Expert Approved Trade Ideas - baoquankhu1.vn
Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Shattuck Labs (NASDAQ:STTK) Coverage Initiated at Needham & Company LLC - Defense World
Volume Recap: Will Shattuck Labs Inc benefit from green energy policies2025 Sector Review & AI Enhanced Trading Alerts - baoquankhu1.vn
Why Shattuck Labs Stock Soared More Than 53% Higher This Week - AOL.com
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI) and Shattuck Labs (STTK) - The Globe and Mail
Portfolio Shifts: Is Shattuck Labs Inc stock a value trapBuy Signal & Short-Term High Return Ideas - baoquankhu1.vn
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut - AOL.com
Shattuck Labs, Inc. Hits New 52-Week High of $5.19 - Markets Mojo
Needham & Company LLC Begins Coverage on Shattuck Labs (NASDAQ:STTK) - MarketBeat
STTK: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Shattuck Labs stock maintained at Buy by TD Cowen on drug data - Investing.com Canada
Shattuck Labs (NASDAQ:STTK) Price Target Raised to $8.00 at Wedbush - MarketBeat
Shattuck Labs (STTK) Receives Buy Rating with $14 Target - GuruFocus
Insights into Shattuck Labs Q4 Earnings - Sahm
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights - Investing News Network
Shattuck Labs (STTK) Anticipates Strong Cash Runway Through 2029 - GuruFocus
Shattuck Labs (STTK) Reports Q4 Revenue and Clinical Trial Progr - GuruFocus
Shattuck Labs 10-K: $1.0M Revenue, $(0.70) EPS on FY Loss Improvement - TradingView
STTK: Net loss improved to $48.8M in 2025 as focus shifted to DR3 platform and cash runway extended into 2029 - TradingView
Shattuck Labs Q4 net loss narrows on lower R&D spend - TradingView
Shattuck Labs (NASDAQ: STTK) cuts 2025 R&D spend, funds operations into 2029 - Stock Titan
Shattuck Labs Advances SL-325 Clinical Trials, Reports Financial Results for Q4 and Full Year 2025 - Quiver Quantitative
BRIEF-Shattuck Labs Q4 Net Income USD -12.593 Million - TradingView
STTK SEC FilingsShattuck Labs, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Shattuck Labs Inc Stock (STTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ashiya Mona | Director |
Aug 25 '25 |
Buy |
0.87 |
6,306,127 |
5,471,826 |
5,255,106 |
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):